Study of the Safety and Effectiveness of NXN-188 for the Treatment of Migraine Headache Without Aura
Status:
Completed
Trial end date:
2010-03-01
Target enrollment:
Participant gender:
Summary
This is a a multi-center, randomized, double-blind, parallel group, and placebo controlled,
two-arm study of a single oral dose of NXN-188 for the treatment of acute migraine headache
without aura. Up to 120 migraineurs will be enrolled. Approximately 60 subjects having a
headache history of migraine without aura will complete each of the two treatment arms to
evaluate NXN-188 600 mg or placebo.